gdc
FDA Approvals, News & UpdatesLeukemiaNewsworthy

Besponsa a New Treatment Option for Patients with Relapsed/Refractory B-Cell ALL

December 2017 Vol 3 No 6

On August 17, 2017, the FDA approved the targeted therapy Besponsa (inotuzumab ozogamicin; from Pfizer) for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The drug blocks cancer growth by binding to B-cell ALL cells that express CD22.

“For adult patients with B-cell ALL whose cancer has not responded to initial treatment or has returned after treatment, life expectancy is typically low. These patients have few treatments available and today’s approval provides a new, targeted treatment option,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

This approval was based on a clinical trial that showed complete response to therapy with Besponsa in more than one-third of patients who received the drug. Serious side effects include liver toxicity, such as veno-occlusive disease or sinusoidal obstruction syndrome, as well as increased risk of death if used after certain stem-cell transplants.

Recommended For You
ImmunotherapyLeukemiaLymphomaPersonalized Medicine
Telling Patients About CAR T-Cell Therapy
By Claire White, BSN, RN, CPHON
Nurse Navigator Claire White describes the way she tells her patients what CAR T-cell therapy is and how it works.
Leukemia
Drugs for Leukemia
Here are the drugs and financial support services available to patients receiving treatment for Leukemia.
Leukemia
Targeted Therapy Better Than Chemotherapy as First Treatment for Some Patients with Chronic Lymphocytic Leukemia
By Dana Taylor
New findings show that starting with a targeted therapy regimen instead of chemotherapy improves outcomes for patients with chronic lymphocytic leukemia, particularly for those under age 70.
Last modified: January 2, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country